Rituximab as a Second-Line Treatment for lymphocytic Vasculitis of the Central Nervous System

被引：0
|
作者：
Anis, Saar [1 ]
Sharabi, Amir [3 ]
Mina, Yair [1 ]
Klein, Ainat [2 ]
Cagnano, Emanuela [4 ]
Elkayam, Ori [3 ]
Gurevich, Tanya [1 ]
机构：
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Neurol, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Rheumatol Inst, Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Inst Pathol, Tel Aviv, Israel
来源：
ISRAEL MEDICAL ASSOCIATION JOURNAL | 2016年 / 18卷 / 10期
关键词：
primary central nervous system angiitis; lymphocytic vasculitis; rituximab; ANGIITIS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：630 / 632
页数：3
相关论文
共 50 条
  • [1] Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma
    Hai-Tao Zhao
    Jing Chen
    Sheng-bin Shi
    Jing Tian
    Rong-Jie Tao
    [J]. Medical Oncology, 2015, 32
  • [2] Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma
    Zhao, Hai-Tao
    Chen, Jing
    Shi, Sheng-bin
    Tian, Jing
    Tao, Rong-Jie
    [J]. MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 5
  • [3] Second-line treatment for primary central nervous system lymphoma
    M Reni
    A J M Ferreri
    E Villa
    [J]. British Journal of Cancer, 1999, 79 : 530 - 534
  • [4] Rituximab is preferable to chemotherapy as second-line treatment for PTLD
    Williams R.
    [J]. Nature Clinical Practice Nephrology, 2006, 2 (5): : 237 - 238
  • [5] Relapsing Primary Central Nervous System Vasculitis Treated With Rituximab
    Messmer, Brady
    Butts, Melissa
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 (06) : E206 - E207
  • [6] Second line treatment for primary central nervous system lymphoma
    Reni, M
    Ferreri, AJM
    Villa, E
    [J]. BRITISH JOURNAL OF CANCER, 1999, 79 (3-4) : 530 - 534
  • [7] INTRAVENOUS RITUXIMAB COMBINED WITH TEMOZOLOMIDE AS A SECOND-LINE THERAPY FOR CD20-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANT LYMPHOMA
    Matsuno, Akira
    Murakami, Mineko
    Nakaguchi, Hiroshi
    Sasaki, Mitsuyoshi
    Uno, Takeshi
    Ide, Fuyuaki
    Tanaka, Hideki
    Fujimaki, Takamitsu
    [J]. NEURO-ONCOLOGY, 2009, 11 (06) : 970 - 970
  • [8] THE TREATMENT OF VASCULITIS OF THE CENTRAL-NERVOUS-SYSTEM
    CALABRESE, LH
    MALLEK, JA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 258 (06): : 778 - 778
  • [9] Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule
    Santisteban, M.
    Nieto, Y.
    De la Cruz, S.
    Aristu, J.
    Zubieta, J. L.
    Fernandez Hidalgo, O.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (07): : 465 - 467
  • [10] Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule
    M. Santisteban
    Y. Nieto
    S. De la Cruz
    J. Aristu
    J. L. Zubieta
    O. Fernández Hidalgo
    [J]. Clinical and Translational Oncology, 2007, 9 : 465 - 467
12345